Literature DB >> 10726623

Serum markers as prognostic factors in epithelial ovarian cancer: an overview.

T Maggino1, A Gadducci.   

Abstract

A comprehensive review of the literature and the authors' personal experience on serum determination of tumour markers in epithelial ovarian cancer can be summarised as follows: CA 125 is the most reliable marker for monitoring the course of epithelial ovarian cancer; CA 125 assay is not an adequate screening test for this malignancy but it can represent an useful adjunct to clinical examination and ultrasound in the differential diagnosis of ovarian masses in postmenopausal women; Serial measurements of CA 125 are useful in monitoring the response to chemotherapy and follow-up. In patients with preoperative positive CA 125 assay, the concomitant determination of other tumour markers does not add further information when compared to CA 125 alone. Conversely in patients with preoperative negative assay the measurement of one or more of other antigens could be of clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726623

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  10 in total

1.  Solid phase extraction of N-linked glycopeptides using hydrazide tip.

Authors:  Jing Chen; Punit Shah; Hui Zhang
Journal:  Anal Chem       Date:  2013-10-30       Impact factor: 6.986

2.  Development and characterization of three novel monoclonal antibodies against CA-125.

Authors:  Tatiana Michurina; Maxim Kerzhner; Boris Klimovich
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-10

3.  GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.

Authors:  H Xiaotong; Melanie-Jane Hannocks; Ian Hampson; Georg Brunner
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

4.  Towards an animal model of ovarian cancer: cataloging chicken blood proteins using combinatorial peptide ligand libraries coupled with shotgun proteomic analysis for translational research.

Authors:  Yingying Ma; Zeyu Sun; Ricardo de Matos; Jing Zhang; Kunle Odunsi; Biaoyang Lin
Journal:  OMICS       Date:  2014-03-24

5.  Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.

Authors:  Yong-Wan Kim; Su Mi Bae; Hyunsun Lim; Yoon Ji Kim; Woong Shick Ahn
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

6.  Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer.

Authors:  Stephen Chee Liang Koh; Chan Yiong Huak; Delfi Lutan; Johny Marpuang; Suwiyoga Ketut; Nyoma Gede Budiana; Agustria Zainu Saleh; Mohamad Farid Aziz; Hariyono Winarto; Heru Pradjatmo; Nguyen Khac Han Hoan; Pham Viet Thanh; Mahesh Choolani
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

7.  "Recurrent multiple cerebral infarctions related to the progression of adenomyosis: a case report".

Authors:  Yasuhiro Aso; Ryo Chikazawa; Yuki Kimura; Noriyuki Kimura; Etsuro Matsubara
Journal:  BMC Neurol       Date:  2018-08-21       Impact factor: 2.474

8.  Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.

Authors:  B R Hoffman; D Katsaros; A Scorilas; P Diamandis; S Fracchioli; I A Rigault de la Longrais; T Colgan; M Puopolo; G Giardina; M Massobrio; E P Diamandis
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

Review 9.  Adoptive immunotherapy against ovarian cancer.

Authors:  Gloria Mittica; Sonia Capellero; Sofia Genta; Celeste Cagnazzo; Massimo Aglietta; Dario Sangiolo; Giorgio Valabrega
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

10.  Diagnostic value of KLK6 as an ovarian cancer biomarker: A meta-analysis.

Authors:  Fan Yang; Zhi-DE Hu; Yingjian Chen; Cheng-Jin Hu
Journal:  Biomed Rep       Date:  2016-04-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.